全文获取类型
收费全文 | 4473篇 |
免费 | 252篇 |
国内免费 | 125篇 |
专业分类
耳鼻咽喉 | 53篇 |
儿科学 | 143篇 |
妇产科学 | 92篇 |
基础医学 | 470篇 |
口腔科学 | 80篇 |
临床医学 | 414篇 |
内科学 | 1170篇 |
皮肤病学 | 65篇 |
神经病学 | 328篇 |
特种医学 | 245篇 |
外科学 | 561篇 |
综合类 | 67篇 |
一般理论 | 3篇 |
预防医学 | 210篇 |
眼科学 | 40篇 |
药学 | 288篇 |
中国医学 | 12篇 |
肿瘤学 | 609篇 |
出版年
2023年 | 28篇 |
2022年 | 40篇 |
2021年 | 81篇 |
2020年 | 60篇 |
2019年 | 72篇 |
2018年 | 104篇 |
2017年 | 84篇 |
2016年 | 80篇 |
2015年 | 126篇 |
2014年 | 123篇 |
2013年 | 205篇 |
2012年 | 289篇 |
2011年 | 274篇 |
2010年 | 150篇 |
2009年 | 138篇 |
2008年 | 187篇 |
2007年 | 274篇 |
2006年 | 202篇 |
2005年 | 198篇 |
2004年 | 189篇 |
2003年 | 171篇 |
2002年 | 157篇 |
2001年 | 135篇 |
2000年 | 123篇 |
1999年 | 116篇 |
1998年 | 75篇 |
1997年 | 62篇 |
1996年 | 66篇 |
1995年 | 51篇 |
1994年 | 39篇 |
1993年 | 36篇 |
1992年 | 63篇 |
1991年 | 75篇 |
1990年 | 79篇 |
1989年 | 79篇 |
1988年 | 87篇 |
1987年 | 59篇 |
1986年 | 59篇 |
1985年 | 59篇 |
1984年 | 34篇 |
1983年 | 35篇 |
1982年 | 19篇 |
1981年 | 17篇 |
1980年 | 16篇 |
1979年 | 29篇 |
1978年 | 17篇 |
1977年 | 28篇 |
1976年 | 19篇 |
1975年 | 23篇 |
1958年 | 14篇 |
排序方式: 共有4850条查询结果,搜索用时 218 毫秒
131.
Eisenhofer G Bornstein SR Brouwers FM Cheung NK Dahia PL de Krijger RR Giordano TJ Greene LA Goldstein DS Lehnert H Manger WM Maris JM Neumann HP Pacak K Shulkin BL Smith DI Tischler AS Young WF 《Endocrine-related cancer》2004,11(3):423-436
Pheochromocytomas are rare catecholamine-producing neuroendocrine tumors that are usually benign, but which may also present as or develop into a malignancy. Predicting such behavior is notoriously difficult and there are currently no curative treatments for malignant tumors. This report follows from a workshop at the Banbury Conference Center, Cold Spring Harbor, New York, on the 16th-18th November 2003, held to review the state of science and to facilitate future progress in the diagnosis and treatment of malignant pheochromocytoma. The rarity of the tumor and the resulting fragmented nature of studies, typically involving small numbers of patients, represent limiting factors to the development of effective treatments and diagnostic or prognostic markers for malignant disease. Such development is being facilitated by the availability of new genomics-based tools, but for such approaches to succeed ultimately requires comprehensive clinical studies involving large numbers of patients, stringently collected clinical data and tumor samples, and interdisciplinary collaborations among multiple specialist centers. Nevertheless, the well-characterized hereditary basis and the unique functional nature of these neuroendocrine tumors provide a useful framework that offers advantages for establishing the pathways of tumorigenesis and malignancy. Such findings may have relevance for understanding the basis of other more common malignancies where similar frameworks are not available. As the relevant pathways leading to pheochromocytoma are established it should be possible to take advantage of the new generation of drugs being developed to target specific pathways in other malignancies. Again the success of this will require well-designed and coordinated multi-center studies. 相似文献
132.
133.
Giordano R Picu A Broglio F Bonelli L Baldi M Berardelli R Ghigo E Arvat E 《Pituitary》2004,7(4):243-248
Ghrelin, a peptide predominantly produced by the stomach, has been discovered as a natural ligand of the GH Secretagogue receptor
type 1a (GHS-R1a), known as specific for synthetic GHS. Ghrelin has recently attracted considerable interest as a new orexigenic
factor. However, ghrelin exerts pleiotropic actions that are explained by the widespread distribution of ghrelin and GHS-R
expression. Besides strong stimulation of GH secretion, the neuroendocrine ghrelin actions also include significant stimulation
of both lactotroph and corticotroph secretion; all these actions depend on acylation of ghrelin in serine-3 that allows binding
and activation of the GHS-R1a. However, GHS-R subtypes are likely to exist; they also bind unacylated ghrelin that is, in
fact, the most abundant circulating form and exerts some biological actions. Ghrelin secretion is mainly regulated by metabolic
signals, namely inhibited by feeding, glucose and insulin while stimulated by energy restriction. The role of glucocorticoids
on ghrelin synthesis and secretion is still unclear although morning ghrelin levels have been found reduced in some patients
with Cushing's syndrome; this, however, would simply reflect its negative association to body mass. Ghrelin, like synthetic
GHS, stimulates ACTH and cortisol secretion in normal subjects and this effect is generally sensitive to the negative glucocorticoid
feedback. It is remarkable that, despite hypercortisolism, ghrelin as well as synthetic GHS display marked increase in their
stimulatory effect on ACTH and cortisol secretion in patients with Cushing's disease. This is even more intriguing considering
that the GH response to ghrelin and GHS is markedly reduced by glucocorticoid excess. It has been demonstrated that the ACTH-releasing
effect of ghrelin and GHS is purely mediated at the central level in physiological conditions; its enhancement in the presence
of ACTH-secreting tumours is, instead, likely to reflect direct action on GHS receptors present on the neoplastic tissues.
In fact, peculiar ACTH hyperresponsiveness to ghrelin and GHS has been observed also in ectopic ACTH-secreting tumours. 相似文献
134.
Assessment of aldehyde dehydrogenase in viable cells 总被引:3,自引:4,他引:3
Jones RJ; Barber JP; Vala MS; Collector MI; Kaufmann SH; Ludeman SM; Colvin OM; Hilton J 《Blood》1995,85(10):2742-2746
Cytosolic aldehyde dehydrogenase (ALDH), an enzyme responsible for oxidizing intracellular aldehydes, has an important role in ethanol, vitamin A, and cyclophosphamide metabolism. High expression of this enzyme in primitive stem cells from multiple tissues, including bone marrow and intestine, appears to be an important mechanism by which these cells are resistant to cyclophosphamide. However, although hematopoietic stem cells (HSC) express high levels of cytosolic ALDH, isolating viable HSC by their ALDH expression has not been possible because ALDH is an intracellular protein. We found that a fluorescent aldehyde, dansyl aminoacetaldehyde (DAAA), could be used in flow cytometry experiments to isolate viable mouse and human cells based on their ALDH content. The level of dansyl fluorescence exhibited by cells after incubation with DAAA paralleled cytosolic ALDH levels determined by Western blotting and the sensitivity of the cells to cyclophosphamide. Moreover, DAAA appeared to be a more sensitive means of assessing cytosolic ALDH levels than Western blotting. Bone marrow progenitors treated with DAAA proliferated normally. Furthermore, marrow cells expressing high levels of dansyl fluorescence after incubation with DAAA were enriched for hematopoietic progenitors. The ability to isolate viable cells that express high levels of cytosolic ALDH could be an important component of methodology for identifying and purifying HSC and for studying cyclophosphamide-resistant tumor cell populations. 相似文献
135.
Busch MP; Laycock M; Kleinman SH; Wages JW Jr; Calabro M; Kaplan JE; Khabbaz RF; Hollingsworth CG 《Blood》1994,83(4):1143-1148
Blood donations in the United States have been screened for antibody to human T-lymphotropic virus type I (HTLV-I) by HTLV-I enzyme immunoassay (EIA) since November 1988. Specimens repeatedly found to be reactive by EIA undergo confirmation by supplementary serologic tests. We assessed the accuracy of blood center testing of 994 HTLV-I EIA repeat-reactive specimens in five US blood centers between November 1988 and December 1991. Of 410 confirmed HTLV-I/II donations, 407 (99.3%) were infected with HTLV-I/II, as determined by polymerase chain reaction (PCR) (403 cases) and by repeat serologic testing (4 cases). The three false- positive results occurred in the first year of testing. Of 425 HTLV- indeterminate specimens, 6 (1.4%) were found to be infected by PCR (5 with HTLV-II and 1 with HTLV-I). None of 159 confirmatory test-negative donations was PCR positive. Of HTLV-I/II-seropositive specimens, 80.2% to 95.4% could be typed as HTLV-I or HTLV-II by type-specific serologic assays. These results support recommendations that HTLV-I/II- seropositive donors should be advised that they are infected with HTLV- I, HTLV-II, or HTLV-I/II (depending on results of type-specific assays). HTLV-indeterminate donors should be advised that their results only rarely indicate HTLV infection. HTLV confirmatory test-negative donors should be reassured that they are not infected with HTLV-I or HTLV-II. 相似文献
136.
Arvat E Di Vito L Lanfranco F Broglio F Giordano R Benso A Muccioli GP Deghenghi R Ghigo E 《Journal of endocrinological investigation》1999,22(2):91-97
Hexarelin (HEX) and GHRP-2 are two synthetic hexapeptides, superanalogs of GHRP-6, belonging to GH secretagogue (GHS) family. GHS act via specific receptors at both the pituitary and the hypothalamic level to stimulate GH release both in animals and in humans. However, GHS also possess significant PRL- and ACTH/cortisol-releasing activity. Tyr-Ala-HEX as well as Tyr-Ala-GHRP-6 are, in turn, synthetic octapeptides generally used to perform binding studies because of their easy iodination. However, their endocrine activities have never been studied in humans. To clarify the endocrine activities of Tyr-Ala-HEX, in 7 young adult volunteers we compared the effects of the maximal effective dose of HEX (2.0 microg/kg i.v.) or GHRP-2 (2.0 microg/kg i.v.) with the same one of Tyr-Ala-HEX on GH, PRL, ACTH and cortisol levels. Basal GH, PRL, ACTH and cortisol levels in all testing sessions were similar. The administration of placebo did not modify hormonal levels. HEX and GHRP-2 administration induced the well known strong GH response (Cmax, mean+/-SE: 77.3+/-6.0 and 74.1+/-12.1 microg/l; AUC, mean+/-SE: 2596.7+/-251.1 and 2480.0+/-343.6 microg*min/l). These responses were similar to that induced by Tyr-Ala-HEX (63.7+/-18.5 microg/l; 1986.6+/-622.4 microg*min/l). Moreover, HEX, GHRP-2 and Tyr-Ala-HEX had the same significant stimulatory effect on PRL (14.9+/-2.5, 12.3+/-2.0 and 10.0+/-1.5 microg/l; 497.8+/-61.8, 480.4+/-66.9 and 415.8+/-58.5 microg*min/l), ACTH (48.0+/-10.1, 51.4+/-10.6 and 44.9+/-12.2 pg/ml; 1531.6+/-235.7, 1586.7+/-277.0 and 1338.1+/-164.5 pg*min/ml) and cortisol (179.9+/-10.0, 181.2+/-14.1 and 149.7+/-20.1 microg/l; 8465.0+/-406.6, 8689.2+/-788.1 and 6295.2+/-797.0 microg*min/l). Also the mean Tmax of the endocrine responses to HEX, GHRP-2 and Tyr-Ala-HEX were similar. In conclusion, the present results demonstrate that in humans Tyr-Ala-HEX is a GH secretagogue as potent as HEX and GHRP-2, two GHRP-6 superanalogs. Tyr-Ala-HEX also shares with HEX and GHRP-2 the same PRL- ACTH- and cortisol-releasing activity. 相似文献
137.
138.
139.
140.